Equities Analysts Set Expectations for BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Research analysts at B. Riley decreased their FY2025 earnings per share estimates for shares of Bicycle Therapeutics in a note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel now forecasts that the company will post earnings per share of ($3.75) for the year, down from their prior estimate of ($3.70). B. Riley currently has a “Neutral” rating and a $17.00 target price on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. B. Riley also issued estimates for Bicycle Therapeutics’ Q4 2025 earnings at ($1.01) EPS, FY2026 earnings at ($4.34) EPS, FY2027 earnings at ($4.38) EPS and FY2028 earnings at ($3.92) EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last announced its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. The business had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s revenue for the quarter was down 30.2% on a year-over-year basis. During the same period in the previous year, the business posted ($1.16) earnings per share.

A number of other equities research analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $33.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. JMP Securities decreased their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 target price on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. Finally, Stephens reissued an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research note on Wednesday, January 22nd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.14.

Bicycle Therapeutics Stock Performance

NASDAQ BCYC opened at $10.38 on Wednesday. Bicycle Therapeutics has a 52-week low of $9.99 and a 52-week high of $28.67. The company has a fifty day moving average of $13.02 and a 200-day moving average of $19.10. The company has a market capitalization of $716.70 million, a P/E ratio of -3.16 and a beta of 1.12.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC purchased a new position in Bicycle Therapeutics during the 3rd quarter valued at $3,406,000. The Manufacturers Life Insurance Company increased its position in shares of Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after buying an additional 32,313 shares during the period. Principal Financial Group Inc. purchased a new stake in Bicycle Therapeutics in the third quarter worth about $10,028,000. State Street Corp boosted its position in Bicycle Therapeutics by 233.5% during the 3rd quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Finally, Jane Street Group LLC grew its holdings in shares of Bicycle Therapeutics by 35.7% during the 3rd quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock worth $457,000 after acquiring an additional 5,310 shares during the period. Institutional investors own 86.15% of the company’s stock.

Insider Buying and Selling at Bicycle Therapeutics

In related news, CEO Kevin Lee sold 9,038 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the transaction, the chief executive officer now owns 495,026 shares in the company, valued at $6,974,916.34. The trade was a 1.79 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Travis Alvin Thompson sold 2,686 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the completion of the sale, the chief accounting officer now owns 32,146 shares of the company’s stock, valued at approximately $482,190. This trade represents a 7.71 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 27,677 shares of company stock worth $392,413. 8.50% of the stock is currently owned by insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.